Strontium ranelate

Drug Profile

Strontium ranelate

Alternative Names: Bivalos; FK 481; Osseor; Ossum; Protaxos; Protelos; Protos; Ranelic acid distrontium salt; S 12911; S-12911-2

Latest Information Update: 24 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier
  • Class Organometallic compounds; Osteoporosis therapies; Thiophenes
  • Mechanism of Action Bone resorption factor inhibitors; Collagen stimulants; Osteoblast stimulants; Osteogenesis stimulants; Osteoprotegerin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Male osteoporosis; Postmenopausal osteoporosis
  • Preregistration Submission Withdrawal Osteoarthritis

Most Recent Events

  • 15 Aug 2015 Servier completes a phase III trial in Postmenopausal osteoporosis in Germany, Hungary, Austria and Belgium (EudraCT2011-000708-17)
  • 04 Jun 2015 Launched for Male osteoporosis in Philippines and Hong Kong (PO) before June 2015
  • 04 Jun 2015 Launched for Postmenopausal osteoporosis in Myanmar, Mexico, Georgia, Serbia, Latvia, Lithuania, Luxembourg, Romania, Peru, Costa Rica, Finland, Guatemala, Honduras, Iceland, Nicaragua, Oman, Panama, Slovakia, Slovenia, El Salvador, Tunisia, Egypt, Bangladesh and India (PO) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top